Table 1.

Summary of recommendation guidelines for breast cancer screening in average-risk women.

Average-risk women	American Cancer Society (ACS)	American College of Obstetricians and Gynecologists (ACOG)	U.S. Preventive Service Task Force (USPSTF)	National Comprehensive Cancer Network (NCCN)	European Society of Breast Imaging (EUSOBI)
Clinical breast examination	Not recommended at any age	Not recommended at any age	Insufficient evidence to recommend for or against clinical breast examination	Women aged 25–39 years every 1–3 years Women aged > 40 years annually	No recommendation
Mammography lower age limit	At the age of 45 years Opportunity to start at 40–45 years	At the age of 40 years No later than age 50 years if not initiated in the 40s	At the age of 50 years Start biennial screening before age 50 years should be an individual decision based on patient beliefs with regard to benefits and harm	At the age of 40 years	At the age of 50 years Opportunity to start at 40–45 years by country-specific priority
Mammography screening interval	Annual for women aged 40–45 years Biennial for women aged ≥ 45 years with the opportunity to continue annually	Annual or biennial based on an informed and shared decision-making process, including benefits and harms of screening, and patients’ beliefs and preferences Biennial screening particularly after age 55 years	Biennial	Annual screening	Biennial Annual screening at 40–49 years
Mammography upper age limit	Continue until life expectancy is <10 years	Continue until age 75 years Beyond age 75 years, the decision to discontinue screening mammography should be based on a shared decision-making process based on health status and longevity	Insufficient evidence to recommend for or against screening beyond age 75 years	Continue until severe co-morbidities limit life expectancy to 10 years or less	Extend screening up to 73 or 75 years